20 July 2021 - Phesgo, a fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection combines two treatments into a single injection.

Roche Canada announce another milestone for Canadian patients with the Health Canada approval and availability of Phesgo  (pertuzumab and trastuzumab) for the treatment of early breast cancer indicated in combination with chemotherapy for the adjuvant treatment of patients with HER2 positive early breast cancer with lymph node positive and/or hormone receptor negative disease. 

Phesgo also received approval in the metastatic setting in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Read Roche press release